Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive statin pharmacogenetic genotyping strategy trial
2023-509418-12-00Phase 4Authorised
- Sponsor
- FIBHULP
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of atorvastatin, simvastatin, pitavastatin, rosuvastatin, pravastatin and 2 more in cardiac event risk and dyslipidemia (2 arms), sponsored by FIBHULP. Primary endpoint: Composite incidence of clinically relevant statin-associated musculoskeletal toxicity. Planned start May 2024; status: authorised.
02
Drugs
atorvastatinsimvastatinpitavastatinrosuvastatinpravastatin
03
Conditions
cardiac event riskdyslipidemia
Beyond the preview
Go deeper on 2023-509418-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509418-12-00.